Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cardiovascular co-morbidity in rheumatic diseases.Vasc Health Risk Manag. 2008; 4: 605-614
- COX inhibitors and thromboregulation.N Engl J Med. 2002; 347 (Available at:): 1025-1026https://doi.org/10.1056/NEJMcibr021805
- Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2.Science (80- ). 2002; 296 (Available at:): 539-541https://doi.org/10.1126/science.1068711
- Renal effects of prostaglandins and cyclooxygenase-2 inhibitors.Electrolyte Blood Press. 2008; 6: 35-41
- Nonsteroidal anti-inflammatory drugs and antihypertensives.Am J Med. 1991; 90: S42-S47
- Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension.Hypertension. 1999; 34: 388-394
- Diclofenac use and cardiovascular risks: Series of nationwide cohort studies.BMJ. 2018; : 362
- Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.J Clin Invest. 2001; 108: 7-13
- The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.Pharmacol Rep. 2005; 57: 66
- Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.N Engl J Med. 2000; 343: 1520-1528
- Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.Lancet. 2008; 372 (Available at:): 1756-1764https://doi.org/10.1016/S0140-6736(08)61490-7
- Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.Am J Med. 2004; 116: 621-629
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.Br Med J. 2006; 332: 1302-1305
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis The CLASS Study: A Randomized Controlled Trial.JAMA. 2000; 284: 1247-1255
- Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.Lancet. 2006; 368: 1771-1781
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.Lancet (London, England). 2013; 382: 769-779
- Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: The Standard care vs. Celecoxib Outcome Trial (SCOT).Eur Heart J. 2017; 38: 1843-1850
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.N Engl J Med. 2016; 375: 2519-2529
- Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.Circulation. 2006; 113: 2906-2913
- Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.Circulation. 2011; 123: 2226-2235
- Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study.Circulation. 2012; 126: 1955-1963
- Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.Arch Intern Med. 2009; 169: 141-149
- Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study.Clin Pharmacol Ther. 2009; 85: 190-197
- Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy—A nationwide study in patients with osteoarthritis.Basic Clin Pharmacol Toxicol. 2019; 124: 629-641
- Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study.Eur Hear Journal Cardiovasc Pharmacother. 2017; 3: 100-107
- Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data.BMJ. 2017; 357
- The Antiplatelet Effect of Six Non-Steroidal Anti-Inflammatory Drugs and Their Pharmacodynamic Interaction With Aspirin in Healthy Volunteers.Am J Cardiol. 2008; 101: 1060-1063
- Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.J Am Coll Cardiol. 2018; 71: 1741-1751
- Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.Lancet (London, England). 2010; 376: 173-179
- Cardiovascular effects of approved drugs for rheumatoid arthritis.Nat Rev Rheumatol. 2021; 17: 270-290
- Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study.Lancet. 2002; 359: 1173-1177
- Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis.Semin Arthritis Rheum. 2020; 50: 598-607
- The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.Ann Rheum Dis. 2015; 74: 480-489
- FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions [Internet].(Available at:)
- Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain the SPACE randomized clinical trial.JAMA. 2018; 319: 872-882
- Association of nonacute opioid use and cardiovascular diseases: a scoping review of the literature.J Am Heart Assoc. 2021; 10: e021260
- Current research on opioid receptor function.Curr Drug Targets. 2012; 13: 230-246
- Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review.Pharmaceutics. 2022; 14: 1190
- Molecular docking evaluation of celecoxib on the boron nitride nanostructures for alleviation of cardiovascular risk and inflammatory.Arab J Chem. 2022; 15 (Available at:): 103521https://doi.org/10.1016/j.arabjc.2021.103521
- Kinesiophobia in rheumatoid arthritis patients: Relationship with quadriceps muscle strength, fear of falling, functional status, disease activity, and quality of life.Arch Rheumatol. 2021; 36: 427-434
- Practice advisory on the appropriate use of NSAIDs in primary care.J Pain Res. 2020; 13: 1925-1939
Article info
Footnotes
Practical advise on NSAID use for PCPs.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
